RGNX
HOLD / NEUTRALMeanRevComposite
44.90
Technical
40.90
Fundamental
46.20
Rank
—
Price
9.66
Hurst
0.24
As of
Aug 31, 2026
Daily
REGENXBIO Inc.
HealthcareBiotechnologyREGENXBIO Inc. is a clinical-stage biotech firm developing treatments that use modified viruses to deliver therapeutic genes into cells affected by genetic disorders. The company's pipeline includes candidates targeting retinal diseases, muscular dystrophy, and metabolic storage disorders, all based on its proprietary viral delivery technology. REGENXBIO also licenses its platform to other pharmaceutical companies and maintains partnerships with AbbVie and Nippon Shinyaku to advance select programs internationally.
Market cap
$542.3M
P/E (trailing)
—
P/E (forward)
-2.74
PEG ratio
—
Dividend yield
—
Beta
0.93
52w range
5.46 – 16.19
Return on equity
-137.63%
Profit margin
-112.58%
Revenue growth
+405.70%
Earnings growth
—
Price history
1Y: 8.22 (-12.2%) · range 5.65–15.98
Cycle position
3/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 100 · STRONG SETUP · exit proximity 0
Conviction
48/ 100 · maturity 100%
VScore.4017
Buildup.2045
EMA entry setup.25100
Fundamentals.1546
Volume profile
POC
10.15
Price vs POC
-19.0%
Overhead supply
69%
Runway
+3.2%
Value area 6.71–12.34 · 69% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| insider-activity | 0.380 | Aug 31, 2026 |
| squeeze-risk | 0.100 | Sep 14, 2026 |
| earnings-surprise | 0.033 | Sep 4, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -2.63% | -0.34% | 3/20d |
| 40d | -2.63% | -0.34% | 3/40d |